Imaging Autotaxin In Vivo with 18F-Labeled Positron Emission Tomography Ligands.

Autotaxin (ATX) is a secreted phosphodiesterase that has been implicated in a remarkably wide array of pathologies, especially in fibrosis and cancer. While ATX inhibitors have entered the clinical arena, a validated probe for positron emission tomography (PET) is currently lacking. With the aim to develop a suitable ATX-targeted PET radioligand, we have synthesized a focused library of fluorinated imidazo[1,2-a]pyridine derivatives, determined their inhibition constants, and confirmed their binding mode by crystallographic analysis. Based on their promising in vitro properties, compounds 9c, 9f, 9h, and 9j were radiofluorinated. Also, a deuterated analog of [18F]9j, designated as [18F]ATX-1905 ([18F]20), was designed and proved to be highly stable against in vivo radiodefluorination compared with [18F]9c, [18F]9f, [18F]9h, and [18F]9j. These results along with in vitro and in vivo studies toward ATX in a mouse model of LPS-induced liver injury suggest that [18F]ATX-1905 is a suitable PET probe for the non-invasive quantification of ATX.

[1]  T. Woltering,et al.  Identification and Preclinical Development of a 2,5,6-Trisubstituted Fluorinated Pyridine Derivative as a Radioligand for the Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors. , 2020, Journal of medicinal chemistry.

[2]  A. Perrakis,et al.  The Structural Binding Mode of the Four Autotaxin Inhibitor Types that Differentially Affect Catalytic and Non-Catalytic Functions , 2019, Cancers.

[3]  T. Pirali,et al.  Applications of Deuterium in Medicinal Chemistry. , 2019, Journal of medicinal chemistry.

[4]  Steven H. Liang,et al.  Synthesis and Preliminary Evaluation of 11C‐Labeled VU0467485/AZ13713945 and Its Analogues for Imaging Muscarinic Acetylcholine Receptor Subtype 4 , 2018, ChemMedChem.

[5]  E. Bednarczyk,et al.  Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals , 2018, The Annals of pharmacotherapy.

[6]  Petra C. Kienesberger,et al.  Lysophosphatidic Acid Signaling in Obesity and Insulin Resistance , 2018, Nutrients.

[7]  Lu Wang,et al.  In Vitro and in Vivo Evaluation of 11C-Labeled Azetidinecarboxylates for Imaging Monoacylglycerol Lipase by PET Imaging Studies. , 2018, Journal of medicinal chemistry.

[8]  N. Triballeau,et al.  Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fib , 2017, Journal of medicinal chemistry.

[9]  U. Ray,et al.  Gene regulatory networking reveals the molecular cue to lysophosphatidic acid‐induced metabolic adaptations in ovarian cancer cells , 2017, Molecular oncology.

[10]  V. Aidinis,et al.  Hepatocyte autotaxin expression promotes liver fibrosis and cancer , 2017, Hepatology.

[11]  Frances Potjewyd,et al.  Rational Design of Autotaxin Inhibitors by Structural Evolution of Endogenous Modulators. , 2017, Journal of medicinal chemistry.

[12]  Jilly F. Evans,et al.  Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[13]  H. Ovaa,et al.  Discovery of potent inhibitors of the lysophospholipase autotaxin. , 2016, Bioorganic & medicinal chemistry letters.

[14]  R. Lafyatis,et al.  An Autotaxin/Lysophosphatidic Acid/Interleukin‐6 Amplification Loop Drives Scleroderma Fibrosis , 2016, Arthritis & rheumatology.

[15]  Willem-Jan Keune,et al.  Steroid binding to Autotaxin links bile salts and lysophosphatidic acid signalling , 2016, Nature Communications.

[16]  Jilly F. Evans,et al.  Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding , 2015, Molecular Pharmacology.

[17]  C. Mamat,et al.  Methods to Increase the Metabolic Stability of 18F-Radiotracers , 2015, Molecules.

[18]  V. Aidinis,et al.  Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer. , 2015, Progress in lipid research.

[19]  A. Abdel-Magid.  Autotaxin Inhibitors May Treat Pain and Osteoarthritis. , 2014, ACS medicinal chemistry letters.

[20]  T. Gant.  Using deuterium in drug discovery: leaving the label in the drug. , 2014, Journal of medicinal chemistry.

[21]  V. Magrioti,et al.  Autotaxin inhibitors: a patent review , 2013, Expert opinion on therapeutic patents.

[22]  T. G. Grunewald,et al.  Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: A focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays , 2013, Biology of the cell.

[23]  J. Chun.  Lysophospholipid Receptors: Signaling and Biochemistry , 2013 .

[24]  H. Ikeda,et al.  Autotaxin in liver fibrosis. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[25]  Christopher S. Stevenson,et al.  Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts. , 2012, Journal of medicinal chemistry.

[26]  H. Ovaa,et al.  Chemical Evolution of Autotaxin Inhibitors , 2012, Chemical reviews.

[27]  H. Nishimasu,et al.  Crystal structure of autotaxin and insight into GPCR activation by lipid mediators , 2011, Nature Structural &Molecular Biology.

[28]  Anastassis Perrakis,et al.  Structural basis for substrate discrimination and integrin binding by autotaxin , 2010, Nature Structural &Molecular Biology.

[29]  J. Gierse,et al.  A Novel Autotaxin Inhibitor Reduces Lysophosphatidic Acid Levels in Plasma and the Site of Inflammation , 2010, Journal of Pharmacology and Experimental Therapeutics.

[30]  D. Herr,et al.  Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. , 2010, Prostaglandins & other lipid mediators.

[31]  G. Mills,et al.  Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression , 2010, British Journal of Cancer.

[32]  Julie Klein,et al.  Lysophosphatidic acid and renal fibrosis. , 2008, Biochimica et biophysica acta.

[33]  M. Gunn,et al.  Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs , 2008, Nature Immunology.

[34]  J. Wain,et al.  The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak , 2008, Nature Medicine.

[35]  B. Gulyás,et al.  PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain , 2004, Synapse.

[36]  S. Hunsucker,et al.  Proteomic analysis of multiple sclerosis cerebrospinal fluid , 2004, Multiple sclerosis.

[37]  H. Dralle,et al.  Expression, regulation and function of autotaxin in thyroid carcinomas , 2004, International journal of cancer.

[38]  G. Mills,et al.  The emerging role of lysophosphatidic acid in cancer , 2003, Nature Reviews Cancer.

[39]  S. Petersen,et al.  Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization , 2001, British Journal of Cancer.

[40]  M. Tsao,et al.  Autotaxin expression in non-small-cell lung cancer. , 1999, American journal of respiratory cell and molecular biology.